



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 29-12-2011.

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL DESIGNS
FOR THE WEEK-ENDING OF 16/12/2011 TO BE PUBLISHED. IN
THE 30/12/2011 GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

12-12-2011

891/201	Dongguan Casun Lampbase Industrial Co., Ltd China (Priority 22-12-2010 China)	”Engaging nail structure of lamp socket”
892/2011	Syngenta Participations AG Switzerland (Priority 14-12-2010 Great Britain)	” Plant growth regulating compounds”
893/2011	Novartis AG Switzerland (Priority 13-12-2010 USA)	“Predictive methods and methods of treating arthritis using il-17 antagonists”
894/2011	Novartis AG Switzerland (Priority 13-12-2010 USA)	“Dimeric iap inhibitors”
895/2011	Novartis AG Switzerland Debiopharma S.A Switzerland (Priority 13-12-2010 USA)	“Pharmaceutical compositions”

13-12-2011

896/2011	Electric Power Research Institute, Inc USA (Priority 23-11-2010 USA)	“Light water reactor primary coolant activity cleanup”
897/2011	Electric Power Research Institute, Inc USA (Priority 23-11-2010 USA)	“Synthesis of sequestration resins for water treatment in light water reactors”

898/2011	Electric Power Research Institute, Inc USA (Priority 23-11-2010 USA)	“Capture, removal, and disposal of radioactive species in an aqueous solution”
----------	---	--

14-12-2011

899/2011	Boehringer Ingelheim International GmbH Germany (Priority 17-12-2010 Europe)	“New compounds, pharmaceutical compositions and uses thereof”
----------	---	--

900/2011	Syngenta Participations AG, Switzerland (Priority 17-12-2010 Europe)	“Insecticidal compounds”
----------	--	--------------------------

901/2011	GlaxoSmithKline Biologicals s.a Belgium (Priority 14-12-2010 USA)	“Novel compositions”
----------	---	----------------------

902/2011	Celanese International Corporation USA (Priority 16-12-2010 USA)	“Eductor-based reactor and pump around loops for production of acetic acid”
----------	---	---

903/2011	Reckitt Benckiser Healthcare International Limited United Kingdom (Priority 15-12-2010 United Kingdom))	“Novel pharmaceutical formulation”
----------	---	------------------------------------

904/2011	IRM LLC Belgium (Priority 08-12-2006 USA) Divisional	Compounds and composition as alk protein inhibitor
----------	---	---

905/2011	E.i. Du Pont De Nemours and Company USA (Priority 29-12-2010 USA)	“Mesoionic pesticides”
----------	--	------------------------

906/2011 Inversiones Hiki6, S.L. "Mobile dosing, mixing and packaging
Spain plant"
(Priority 16-12-2010 Europe)

15-12-2011

907/2011 Lenzing Aktiengesellschaft "Flame retardant cellulosic man-made
Austria fibers"
(Priority 20-12-2010 Austria)

908/2011 Novartis AG "Crystalline forms of 5-chloro-n2-(2-
Switzerland isopropoxy-5-methyl-4-piperidin-4-yl-
(Priority 17-12-2010 USA) phenyl)-n4-[2-(propane-2-sulfonyl)-
phenyl]-pyrimidine-2, 4-diamine"

909/2011 Sanofi "M1RNAs Joint Disease"
France
(Priority 17-12-2010 Europe)

910/2011 Loesche GmbH "Method for grinding mill material and
Germany roller mill"
(Priority 16-12-2010 Europe)

911/2011 Global 1 Enterprises Inc "ATM/KIOSK Cash Acceptance"
USA
(Priority 16-12-2010 USA)

912/2011 AstraZeneca AB "Novel compound"
Sweden
Dainippon Sumitomo Pharma
Co.,Ltd
Japan
(Priority 16-12-2010 USA)

16-12-2011

913/2011 Pfizer Inc. "Novel fused pyridine compounds as
USA casein kinase inhibitors"
(Priority 20-12-2010 USA)

914/2011	Prof. Dr. Muhammad Gulfraz Zahuid Anwar Muhammad Imran Abdul Rehman Agricultural Biochemistry Lab, University Institute of Biochemistry and Biotechnology, PMAS Arid Agriculture University Rawal pindi Pakistan	“A study on bioethanol production from rice polish by using fermentation biotechnology”
915/2011	GlaxoSmithKline LLC USA (Priority 20-12-2010 USA)	“Novel pharmaceutical composition”
916/2011	Novertis AG Switzerland	“2,3,5-trisubstituted thiophene compounds and uses thereof”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

608/1999 Glexo Group Limited
 United Kingdom

“Calcium (3s) tetrahydro-3-furanyl (sr,2r)-3-[[4-aminophenyl)sulfonyl (isobutyl) amino]-1-benzyl-2(phosphonooxy)porpylcarbomate”

CO7F 9/655

141294

The present invention relates to calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[4-aminophenyl)sulfonyl]-(isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate Form I and pharmaceutical composition thereof.


78/2000 University of Virginia
 Patent Foundation
 USA

“A (cycloalkylalkynyl)adenosine compound”

A61K 31/70, A61P 29/00, C07H 19/16

141295

Compound of the formula (I)



wherein is provided to treat inflammatory conditions with certain A2A adenosine receptor antagonists.


1307/2006 Aventis Pharmaceuticals
Inc.
USA

“Pyrimidine amide compounds”

C07D 239/28, C07D 401/14, C07D 403/12, C07D
413/04, A61K 31/506, A61P 11/00

141296

This invention is directed to a compound of formula
(I):



wherein R¹, R², R³ and L¹ are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

747/2007 F.F. Seeley Nominees Pty
Limited,
Australia

“Method and Materials for Improving Evaporative
Heat Exchanger”

B32B 3/28, F 24F 6/00

141297

A corrugated laminate material for use in an evaporative heat exchanger, said material including a water retaining medium having a wettable surface and an opposed vapour resistant surface.


952/2008 Sanofi-Aventis
France

“Substituted 6-triazolopyridazine sulphanyl
benzothiazole/ benzimidazole compound”

C07D 87/04, C07D 237/06, C07D 249/10, C07D
235/04, C07D 277/82, A61K 31/5025, A61P 35/00

141298

The invention relates to a compound of formula (I):



in which bond represents a single or double bond;
Ra represents H, Hal, alkoxy, 0-cycloalkyl,
heteroaryl, phenyl, NHCOalk, NHCOcycloalk or
NR₁R₂; X represents S, SO or SO₂; A represents
NH or S; W represents H, alkyl or COR with R
representing cycloalkyl; alkyl optionally substituted
with NR₃R₄, alkoxy, hydroxyl, phenyl, heteroaryl
or heterocycloalkyl; alkoxy optionally substituted
with NR₃R₄, i.e. an O-(CH₂)_n-NR₃R₄ radical, an O-
phenyl radical or an O-(CH₂)_n-phenyl radical, with
phenyl optionally substituted and n= 1 to 4; or the
NR₁R₂ radical;

R₁ represents H or alk and R₂ represents H,
cycloalkyl or alkyl; R₃ and R₄ represent H, alk,
cycloalkyl, heteroaryl or phenyl; R₁, R₂ and/or R₃,
R₄ form, with N, a ring optionally containing O, S,
N and/or NH; all heterocycloalkyls, heteroaryls,
phenyls and cyclic groups being optionally
substituted;

as medicament, especially as MET inhibitor.


1348/2008 Glaxo Group Limited
United Kingdom

“Process for the preparation of Calcium (3S) tetrahydro-3-furanyl(1S,2R)- 3-[[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonoxy) propylcarbamate”

C07F 9/655


141299

The invention relates to a process for the preparation of a stable crystalline form of calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[[(4-aminophenyl)sulfonyl]isobutyl)amino]-1-benzyl-2-(phosphonoxy) propylcarbamate, a compound of formula (I)



comprising

- 1) reacting a compound of formula (II)



with a phosphorylating agent:

- ii) reducing the resultant compound with a reducing agent in a suitable solvent; and
- iii) adding to the resultant compound a source of calcium ions in the presence of a suitable solvent.


569/2009 H. Lundbeck A/S
Denmark

“Isoquinoline Compound”

C07D 401/04, C07D 40/14, C07D 403/04, C07D
417/04, A61K 31/4725, A61P 25/18

141300

A compound according to formula I



wherein A represent N, CH or CR¹:
each R¹ independently represents hydrogen. C₁₋₆alkyl. C₂₋₆alkenyl, C₂₋₆alkynyl, -C(0)-C₂₋₆alkenyl, -C(0)-C₂₋₆alkynyl, -C(0)-O-C₁₋₆alkyl, -C(0)-O-C₂₋₆alkenyl, -C(0)-O-C₂₋₆alkynyl or phenyl, wherein said phenyl, C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl is optionally substituted with one or more substituents selected from halogen. hydroxyl. haloC₁₋₆alkyl, nitro, C₁₋₆alkoxy. and NR²R³;
X represents hydrogen. C₁₋₆alkyl or -CR^aR^b-X', wherein r represents a monocyclic saturated moiety having 5-6 ring atoms one of which is N and wherein one or two additional ring atom may be a hetero atom selected from N, O and S, which monocyclic ring may be substituted with one or more substituted W, wherein W is selected from C₁₋₆alkyl. C₂₋₆alkenyl, C₂₋₆alkynyl, or (=O):
R^a and R^b each individually represent hydrogen - CH₃ or halogen:
Y represents a hetero aromatic moiety having 5-6 ring atoms, wherein 1-4 of said ring atoms are selected from N, O and S, which hetero aromatic moiety may optionally be benzofused, and which hetero aromatic moiety may be substituted with one or more substituted Z, wherein Z is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, cyano, halogen, hydroxy, C₁₋₆alkoxy. C₁₋₆haloalkyl, and NR²R³:
wherein each of R² and R³ independently represents hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, hydroxyC₁₋₆alkyl, or haloC₁₋₆alkyl;


970/2009 Eli Lilly and company
USA

“Substituted 4-imidazol-2-yl piperidine compound”

A61K 45/00

141301

The present invention provides a compound of the formula I:



wherein the variables R¹, R², R³, R⁶, R⁷, R⁸, W, X and Y have meanings as defined in the Specification.

The present invention also provides a pharmaceutical composition comprising compound of Formula I, for treating glioblastoma multiforme.


400/2011 Sanofi
France

“Pharmaceutically acceptable salt and isomer of a substituted 6-triazolopyridazine sulphanyl benzothiazole/benzimidazole compound”

C07D 487/04, C07D 237/06, C07D 249/10, C07D 235/04, A61K 31/5025

141302

The invention relates to a pharmaceutically acceptable salt and isomer of a compound of formula (I):



in which bond represents a single or double bond; Ra represents H, Hal, alkoxy, 0-cycloalkyl, heteroaryl, Phenyl, NHCOalk, NHCOcycloalk or NR₁R₂; X represents S, SO or SO₂; A represents NH or S; W represents H, alkyl or COR with R representing cycloalkyl; alkyl optionally substituted with NR₃R₄, alkoxy, hydroxyl, phenyl, heteroaryl or heterocycloalkyl; alkoxy optionally substituted with NR₃R₄, i.e. an 0-(CH₂)_n-NR₃R₄ radical, an 0-phenyl radical or an 0-(CH₂)_n-phenyl radical, with phenyl optionally substituted and n= 1 to 4; or the NR₁R₂ radical:

R₁ represents H or alk and R₂ represents H, cycloalkyl or alkyl; R₃ and R₄ represent H, alk, cycloalkyl, heteroaryl or phenyl; R₁, R₂ and for R₃, R₄ form, with N, a ring optionally containing O, S, N and/or NH: all heterocycloalkyls, heteroaryls, phenyls and cyclic groups being optionally substituted:

as medicament, especially as MET inhibitor.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
141171	Wyeth USA.	90/2002
41172	Novartis AG., Switzerland.	1111/2003
141173	Tetra Laval Holdings & Finance SA Pully,	398/2005
141174	Novartis AG., Switzerland.	860/2005
141175	Les Laboratoires Servier, France.	902/2006
141176	Les Laboratoires Servier, France.	904/2006
141177	China Petroleum & Chemicals Corporation P.R. China Research Institute of Petroleum Processing Sinopec, P. R. China.	824/2007
141178	Les Laboratoires Servier, France.	930/2008
141179	Abbott GmbH & Co., KG, Germany.	1127/2008
141180	AstraZeneca AB, Sweden.	625/2003
141181	Aventis Pharmaceuticals Inc., USA.	322/2004

141182	Dr. Arfa Yasmin, Mrs. Rehana Jafri Dr. Amir Ahmed, Irshad Ahmed Khan, PCSIR Lab. Complex, Karachi – Pakistan.	460/2007
141183	Novartis AG., Switzerland.	891/2008
141184	AstraZeneca AB, Switzerland.	179/2011
141185	Bayer Aktiengesellschaft Germany.	289/2001
141186	Picanol N.V., Belgium.	329/2006
141187	Wyeth, USA.	966/2006
141188	Abbott GmbH & Co., KG, Germany.	1300/2008
141189	Tetra Laval Holdings & Finance SA Switzerland.	693/2010
141190	Wyeth, USA.	77/2011
141191	Deere & Company, USA.	695/2007
141192	Dr. Suhail Zaki Farooqui, Karachi – Pakistan.	657/2010
141193	Glaxo Group Limited, United Kingdom.	1645/2006
141194	Ammonia Casale S.A., Switzerland.	778/2008

141195	Sumra Naeem Uzma Zafar PCSIR, Lahore – Pakistran.	390/2009
141196	Tetra Laval Holdings & Finance SA Switzerland.	250/2010
141197	N.V. Organon, Netherland.	1252/2005
141198	Schlumberger Technology BV, Netherland.	789/2009
141199	Takeda Pharmaceutical Co. Limited, Japan.	93/2009
141200	Unilever Plc, United Kingdom.	3/2008
141201	Celanese International Corporation, USA.	1125/2005
141202	Cool Energy Limited, Australia.	124/2008
141203	Picanol N.V, Belgium	801/2008
141204	The Wellcome Foundation Limited, Great Britain.	108/1998
141205	The Wellcome Foundation Limited, Great Britain.	169/2011
141206	Bayer Cropscience AG, Germany.	455/1999
141207	Brasilata SA Embalagens Metalicas Brazil.	1061/2005
141208	Sanofi Aventis, France.	436/2006
141209	Honda Motor Co., Ltd., Japan.	1500/2006

141210	Novartis AG., Switzerland.	1455/2008
141211	Bayer Schering Pharma Aktiengesellschaft, Germany.	935/2009
141212	Johnson Matthey PLC, United Kingdom.	252/2005
141213	Ten Cate Advanced Textiles B.V., Netherland.	1293/2008
141214	Terre Armee Internationale, France.	249/2007
141215	Sanofi Aventis, France.	888/2007
141216	Mujeeb ur Rehman Alvi, Karachi – Pakistan.	563/2010
141217	Pierre Fabre Medicament, France.	747/2010

CEASED CASES

The following patents have been ceased due to non payment of Renewal fee.

<u>S.N</u>	<u>File No.</u>	<u>Reg.No</u>	<u>Title</u>	<u>Representative</u>	<u>Applicant</u>
1	824/1997	135958	<i>METHOD FOR PREPARING SUBSTITUTED -4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS.</i>	United Trademark & Patent Services, West End Building, 61-The Mall, Lahore-54000, Pakistan.	Smithkline Beecham Corporation
2	1061/1998	136534	<i>A LUBRICATING GREASE COMPRISING A BASE OIL AND A THICKENER IN COMBINATION WITH MOLYBDENUM DITHIOCARBAMATE,ZINC NEPHTHENATE AND ONE OR MORE METAL DITHIOPHOSPHATE.</i>	Vellani & Vellani , 148, 18th East Street, Phase 1, Defence Officers' Housing Authority, Karachi-75500 (Pakistan)	Lurgi Zimmer GmbH
3	1040/1998	136634	<i>METHOD FOR PREPARING SUBSTITUTED -4-PHENYL-4-CYANOCYCLOHEXANOIC ACIDS.</i>	United Trademark & Patent Services, West End Building, 61-The Mall, Lahore-54000, Pakistan.	Smithkline Beecham Corporation

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>15-12-2011</u>			
1	15985	Under Water LED (Class-03)	Koninklijke Philips Electronics N.V.
2	15986	Generator (Class-01)	Loncin Motor Company Ltd
<u>16-12-2011</u>			
3	15987	Plastic Bottle (Class-03)	Century Cosmetics (Regd)
4	15988	Container (Class-03)	UNILEVER PLC,
5	15989	Container (Class-03)	UNILEVER PLC,

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>12-12-2011</u>			
1	12238	Insect Repellant Device (Class-03)	Reckitt Benckiser (Australia) Pty Limited
2	12239	Insect Repellant Device (Class-03)	Reckitt Benckiser (Australia) Pty Limited
<u>13-12-2011</u>			
3	15753	Automobile (Class-1)	Chongqing Sokon Industry Group Stock Co., Ltd
<u>16-12-2011</u>			
4	15669	A Shroud for a Motorcycle (Class-03)	Honda Motor Co., Ltd.
5	15670	A Front Cowl for a Motorcycle (Class-03)	Honda Motor Co., Ltd.
6	15683	A Hood for Automobile (Class-01)	Honda Motor Co., Ltd.
7	15684	An Automobile (Class-01)	Honda Motor Co., Ltd.
8	15685	A Rear Combination Lamp for an Automobile (Class-03)	Honda Motor Co., Ltd.
9	15686	An Automobile (Class-01)	Honda Motor Co., Ltd.
10	15687	A Steering Wheel for an Automobile (Class-03)	Honda Motor Co., Ltd.
11	15688	A Fender for an Automobile (Class- 01)	Honda Motor Co., Ltd.
12	15689	An Instrument Panel for an Automobile (Class-03)	Honda Motor Co., Ltd.
13	15690	A Front Bumper for an Automobile (Class-01)	Honda Motor Co., Ltd.
14	15691	A Grill for an Automobile (Class-01)	Honda Motor Co., Ltd.

(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215488